参考文献/References:
[1] KUZMA L, MALYSZKO J, KURASZ A, et al. Impact of renal function on patients with acute coronary syndromes: 15,593 patient-years study [J]. Ren Fail, 2020, 42(1): 881-9.
[2] MOHAMMED N M, MAHFOUZ A, ACHKAR K, et al. Contrast-induced Nephropathy [J]. Heart Views, 2013, 14(3): 106-16.
[3] KELLUM J A, LAMEIRE N, GROUP K A G W. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1) [J]. Crit Care, 2013, 17(1): 204.
[4] SUN G, CHEN P, WANG K, et al. Contrast-Induced Nephropathy and Long-Term Mortality After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction [J]. Angiology, 2019, 70(7): 621-6.
[5] YANG Y, GEORGE K C, LUO R, et al. Contrast-induced acute kidney injury and adverse clinical outcomes risk in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis [J]. BMC Nephrol, 2018, 19(1): 374.
[6] MA K, LI J, SHEN G, et al. Development and Validation of a Risk Nomogram Model for Predicting Contrast-Induced Acute Kidney Injury in Patients with Non-ST-Elevation Acute Coronary Syndrome Undergoing Primary Percutaneous Coronary Intervention [J]. Clin Interv Aging, 2022, 17: 65-77.
[7] LUCREZIOTTI S, CENTOLA M, SALERNO-URIARTE D, et al. Female gender and contrast-induced nephropathy in primary percutaneous intervention for ST-segment elevation myocardial infarction [J]. Int J Cardiol, 2014, 174(1): 37-42.
[8] HE H, CHEN X R, CHEN Y Q, et al. Prevalence and Predictors of Contrast-Induced Nephropathy (CIN) in Patients with ST-Segment Elevation Myocardial Infarction (STEMI) Undergoing Percutaneous Coronary Intervention (PCI): A Meta-Analysis [J]. J Interv Cardiol, 2019, 2019: 2750173.
[9] KHALFALLAH M, ALLAITHY A, MARIA D A. Incidence, Predictors and Outcomes of Contrast Induced Nephropathy in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention [J]. Glob Heart, 2021, 16(1): 57.
[10] YILDIRIM E, ERMIS E, CENGIZ M. Inflammatory markers of contrast-induced nephropathy in patients with acute coronary syndrome [J]. Coron Artery Dis, 2020, 31(3): 279-83.
[11] WI J, KO Y G, SHIN D H, et al. Prediction of Contrast-Induced Nephropathy With Persistent Renal Dysfunction and Adverse Long-term Outcomes in Patients With Acute Myocardial Infarction Using the Mehran Risk Score [J]. Clin Cardiol, 2013, 36(1): 46-53.
[12] ANDò G, MORABITO G, DE GREGORIO C, et al. Age, glomerular filtration rate, ejection fraction, and the AGEF score predict contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention [J]. Catheter Cardiovasc Interv, 2013, 82(6): 878-85.
[13] LIU Y H, JIANG L, DUAN C Y, et al. Canada Acute Coronary Syndrome Score: A Preprocedural Risk Score for Contrast-Induced Nephropathy After Primary Percutaneous Coronary Intervention [J]. Angiology, 2017, 68(9): 782-9.
[14] KURTUL A, YARLIOGLUES M, DURAN M. Predictive Value of CHA2DS2-VASC Score for Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Acute Coronary Syndrome [J]. Am J Cardiol, 2017, 119(6): 819-25.
[15] LIU C W, LIAO P C, CHEN K C, et al. SYNTAX Score of Infarct-Related Artery Other Than the Number of Coronary Balloon Inflations and Deflations as an Independent Predictor of Contrast-Induced Acute Kidney Injury in Patients with ST-Segment Elevation Myocardial Infarction [J]. Acta Cardiol Sin, 2017, 33(4): 362-76.
[16] ZAKI H A, BASHIR K, IFTIKHAR H, et al. Evaluating the Effectiveness of Pretreatment With Intravenous Fluid in Reducing the Risk of Developing Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis [J]. Cureus, 2022, 14(5): e24825.
[17] WANG Z, SONG Y, A G, et al. Role of Hydration in Contrast-Induced Nephropathy in Patients Who Underwent Primary Percutaneous Coronary Intervention [J]. Int Heart J, 2019, 60(5): 1077-82.
[18] LIU Y, HONG D, WANG A Y, et al. Effects of intravenous hydration on risk of contrast induced nephropathy and in-hospital mortality in STEMI patients undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials [J]. BMC Cardiovasc Disord, 2019, 19(1): 87.
[19] LIU Y, TAN N, HUO Y, et al. Hydration for prevention of kidney injury after primary coronary intervention for acute myocardial infarction: a randomised clinical trial [J]. Heart, 2022, 108(12): 948-55.
[20] THAYSSEN P, LASSEN J F, JENSEN S E, et al. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial [J]. Circ Cardiovasc Interv, 2014, 7(2): 216-24.
[21] WEISBORD S D, GALLAGHER M, JNEID H, et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine [J]. N Engl J Med, 2018, 378(7): 603-14.
[22] NEUMANN F J, SOUSA-UVA M, AHLSSON A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization [J]. Eur Heart J, 2019, 40(2): 87-165.
[23] LAWTON J S, TAMIS-HOLLAND J E, BANGALORE S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [J]. Circulation, 2022, 145(3): e18-e114.
[24] MARENZI G, COSENTINO N, WERBA J P, et al. A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes [J]. Int J Cardiol, 2015, 183: 47-53.
[25] TROPEANO F, LEONCINI M, TOSO A, et al. Impact of Rosuvastatin in Contrast-Induced Acute Kidney Injury in the Elderly: Post Hoc Analysis of the PRATO-ACS Trial [J]. J Cardiovasc Pharmacol Ther, 2016, 21(2): 159-66.
[26] FU N, LIANG M, YANG S. High Loading Dose of Atorvastatin for the Prevention of Serum Creatinine and Cystatin C-Based Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention [J]. Angiology, 2018, 69(8): 692-9.
[27] SREENIVASAN J, KHAN M S, LI H, et al. Statins and Incidence of Contrast-Induced Acute Kidney Injury Following Coronary Angiography - Five Year Experience at a Tertiary Care Center [J]. Cardiovasc Revasc Med, 2019, 20(8): 654-8.
[28] MACDONALD D B, HURRELL C D, COSTA A F, et al. Canadian Association of Radiologists Guidance on Contrast-Associated Acute Kidney Injury [J]. Can J Kidney Health Dis, 2022, 9: 20543581221097455.
[29] GUO Z, LIU J, LEI L, et al. Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials [J]. BMJ Open, 2020, 10(10): e039009.
[30] WANG N, QIAN P, KUMAR S, et al. The effect of N-acetylcysteine on the incidence of contrast-induced kidney injury: A systematic review and trial sequential analysis [J]. Int J Cardiol, 2016, 209: 319-27.
[31] GARCIA S, BHATT D L, GALLAGHER M, et al. Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes Following Percutaneous Coronary Intervention: A Subgroup Analysis of the PRESERVE Trial [J]. JACC Cardiovasc Interv, 2018, 11(22): 2254-61.
[32] HUANG J W, LAHEY B, CLARKIN O J, et al. A Systematic Review of the Effect of N-Acetylcysteine on Serum Creatinine and Cystatin C Measurements [J]. Kidney Int Rep, 2021, 6(2): 396-403.
[33] BOLOGNESE L, FALSINI G, SCHWENKE C, et al. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial) [J]. Am J Cardiol, 2012, 109(1): 67-74.
[34] ENG J, WILSON R F, SUBRAMANIAM R M, et al. Comparative Effect of Contrast Media Type on the Incidence of Contrast-Induced Nephropathy: A Systematic Review and Meta-analysis [J]. Ann Intern Med, 2016, 164(6): 417-24.
[35] MCCULLOUGH P, NG C S, RYAN M, et al. Major Adverse Renal and Cardiovascular Events following Intra-Arterial Contrast Media Administration in Hospitalized Patients with Comorbid Conditions [J]. Cardiorenal Med, 2021, 11(4): 193-9.
[36] JOVIN I S, WARSAVAGE T J, PLOMONDON M E, et al. Iso-osmolar versus low-osmolar contrast media and outcomes after percutaneous coronary intervention: Insights from the VA CART Program [J]. Catheter Cardiovasc Interv, 2022, 100(1): 85-93.
[37] BROWN J R, ROBB J F, BLOCK C A, et al. Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury? [J]. Circ Cardiovasc Interv, 2010, 3(4): 346-50.
[38] ANDO G, DE GREGORIO C, MORABITO G, et al. Renal function-adjusted contrast volume redefines the baseline estimation of contrast-induced acute kidney injury risk in patients undergoing primary percutaneous coronary intervention [J]. Circ Cardiovasc Interv, 2014, 7(4): 465-72.
[39] KUROGI K, ISHII M, SAKAMOTO K, et al. Persistent Renal Dysfunction in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction [J]. J Am Heart Assoc, 2019, 8(23): e014096.
[40] MARENZI G, MAZZOTTA G, LONDRINO F, et al. Post-procedural hemodiafiltration in acute coronary syndrome patients with associated renal and cardiac dysfunction undergoing urgent and emergency coronary angiography [J]. Catheter Cardiovasc Interv, 2015, 85(3): 345-51.
[41] CRUZ D N, GOH C Y, MARENZI G, et al. Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review [J]. Am J Med, 2012, 125(1): 66-78 e3.
[42] OYAMADA N, HAMANAKA I, FUJIOKA A, et al. Effectiveness of high flow-volume intermittent hemodiafiltration during and after intervention to prevent contrast-induced nephropathy in patients with advanced chronic kidney disease: A pilot study [J]. Catheter Cardiovasc Interv, 2020, 96(6): 1174-81.
[43] WANG C, CHEN W, YU M, et al. Comparison of acute kidney injury with radial vs. femoral access for patients undergoing coronary catheterization: An updated meta-analysis of 46,816 patients [J]. Exp Ther Med, 2020, 20(5): 42.
[44] WANG Y Y, LI T, LIU Y W, et al. Ischemic Postconditioning Before Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction Reduces Contrast-induced Nephropathy and Improves Long-term Prognosis [J]. Arch Med Res, 2016, 47(6): 483-8.
[45] ZHOU F, SONG W, WANG Z, et al. Effects of remote ischemic preconditioning on contrast induced nephropathy after percutaneous coronary intervention in patients with acute coronary syndrome [J]. Medicine (Baltimore), 2018, 97(2): e9579.
相似文献/References:
[1]李润土,何泉.光学相干断层成像在急性冠脉综合征介入治疗中的应用[J].心血管病学进展,2019,(6):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
LI Runtu,HE Quan.Application of Optical Coherent Tomography in Interventional Treatment of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(2):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
[2]郑晓雪 季福绥.急性冠脉综合征患者发生急性肾损伤的临床进展[J].心血管病学进展,2019,(5):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
ZHENG Xiaoxue,JI Fusui.Acute Kidney Injury in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(2):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
[3]周小琳 何泉.替格瑞洛在急性冠脉综合征合并慢性肾脏病患者中的应用研究进展[J].心血管病学进展,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
ZHOU Xiaolin,HE Quan.Ticagrelor in Acute Coronary Syndrome with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2019,(2):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
[4]吕俊兴 许海燕.急性冠脉综合征危险评分的研究进展[J].心血管病学进展,2019,(9):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
LU Junxing,XU Haiyan.Risk Scores of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(2):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
[5]吕颖 胡思宁 于波 贾海波.斑块侵蚀发病机制的最新研究进展[J].心血管病学进展,2020,(1):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
LU Ying,HU Sining,YU Bo,et al.Pathogenic Mechanisms of Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(2):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
[6]段继坤,林志,杨帆,等.斑块侵蚀引起的急性冠脉综合征的研究新进展[J].心血管病学进展,2020,(3):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
DUAN Jikun,LIN Zhi,YANG Fan,et al.Acute Coronary Syndrome Caused by Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(2):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
[7]陈凯磊 胡闻竹 苏冠华.P2Y12抑制剂与癌症风险的相关性研究进展[J].心血管病学进展,2020,(8):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
CHEN Kailei,HU Wenzhu,SU Guanhua.Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk[J].Advances in Cardiovascular Diseases,2020,(2):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
[8]肖雨尘 赵仙先 马丽萍.急性冠脉综合征患者提前停服替格瑞洛现象的研究进展[J].心血管病学进展,2020,(11):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
Acute Coronary Syndrome.Premature Ticagrelor Discontinuation in Patients with[J].Advances in Cardiovascular Diseases,2020,(2):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[9]冯洁渊 .中性粒细胞/淋巴细胞比值和血小板/淋巴细胞比值与急性冠脉综合征的关系研究进展[J].心血管病学进展,2020,(12):1276.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.013]
FENG Jieyuan.The Relationship Between Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio and Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2020,(2):1276.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.013]
[10]魏倩 梁岩.高敏心肌肌钙蛋白在急性冠脉综合征患者中的临床应用进展[J].心血管病学进展,2021,(5):396.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.003]
[11]张昭,王仁学,毛琳霜,等.尿素氮/肌酐比值对于非ST段抬高急性冠脉综合征患者经皮冠脉介入术后对比剂肾病的预测价值[J].心血管病学进展,2021,(8):748.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.018]
ZHANG Zhao,WANG Renxue,MAO Linshuang,et al.Predictive Value of Urea-Nitrogen/Creatinine Ratio for Contrast Induced Nephropathy in Patients with Non-ST-Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2021,(2):748.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.018]